Lunai Bioworks (LNAI) Share-based Compensation (2016 - 2026)
Lunai Bioworks (LNAI) posted quarterly Share-based Compensation of $168993.0 for Q1 2026, down 88.73% year-over-year from $1.5 million in Q1 2025, and up 31.19% quarter-over-quarter from $128819.0 in Q4 2025.
Lunai Bioworks (LNAI) Share-based Compensation (2016 - 2026) Analysis & Trends
Lunai Bioworks' Share-based Compensation history runs 11 years deep, the most recent figure standing at $168993.0 for Q1 2026.
- In Q1 2026, Share-based Compensation fell 88.73% year-over-year to $168993.0; the TTM figure through Mar 2026 stood at $1.4 million (down 57.55% YoY), while the FY2025 annual figure was $3.3 million, down 29.1% from the prior year.
- Share-based Compensation for Q1 2026 stood at $168993.0, up from $128819.0 in the prior quarter.
- The five-year high for Share-based Compensation was $1.9 million in Q1 2024, with the low at $128819.0 in Q4 2025.
- The 5-year median for Share-based Compensation is $612885.0 (2023), against an average of $716827.9.
- The sharpest annual moves came in 2023 and 2026: Share-based Compensation soared 332.65% in 2023, then tumbled 88.73% in 2026.
- Lunai Bioworks' Share-based Compensation stood at $819955.0 in 2022, then plunged by 43.24% to $465372.0 in 2023, then advanced by 20.04% to $558631.0 in 2024, then plunged by 76.94% to $128819.0 in 2025, then jumped by 31.19% to $168993.0 in 2026.
- Business Quant data shows LNAI's Share-based Compensation at $168993.0 in Q1 2026, $128819.0 in Q4 2025, and $181312.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 86.63 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 41.25 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 28.05 Mn |
| 10 | Lunai Bioworks | 6.87 Mn | 3.72 Mn | 20,942.00 | 168,993.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 168,993.00 |
| Mar 31, 2026 | 168,993.00 |
| Dec 31, 2025 | 128,819.00 |
| Dec 31, 2025 | 128,819.00 |
| Sep 30, 2025 | 181,312.00 |
| Sep 30, 2025 | 181,312.00 |
| Jun 30, 2025 | 897,813.00 |
| Jun 30, 2025 | 897,813.00 |
| Mar 31, 2025 | 1.50 Mn |
| Mar 31, 2025 | 1.50 Mn |
| Dec 31, 2024 | 558,631.00 |
| Dec 31, 2024 | 558,631.00 |
| Sep 30, 2024 | 357,648.00 |
| Sep 30, 2024 | 357,648.00 |
| Jun 30, 2024 | 828,471.00 |
| Jun 30, 2024 | 828,471.00 |
| Mar 31, 2024 | 1.86 Mn |
| Mar 31, 2024 | 1.86 Mn |
| Dec 31, 2023 | 465,372.00 |
| Dec 31, 2023 | 465,372.00 |